Abu Dhabi Biobank Collaborates with Japanese Firm for Innovative Stem Cell Therapies

Post by : Bianca Suleiman

In a significant move for the UAE's healthcare landscape, Abu Dhabi Biobank has forged a strategic alliance with Japan's Human Life CORD (HLC) to advance and implement umbilical cord-derived stem cell therapies. This initiative is backed by the Department of Health – Abu Dhabi (DoH) and the global health firm M42.

This collaboration marks a leap forward in providing cutting-edge stem cell treatments across the UAE and the broader MENA region, further establishing Abu Dhabi as a global center for healthcare innovation, life sciences, and personalized medicine.

Uniting Abu Dhabi Biobank's sophisticated biobanking systems and research capabilities with HLC’s proficiency in mesenchymal stem cell (MSC) technology, the partners aim to develop personalized regenerative therapies to address pressing health issues in the region.

The DoH will support ongoing research and innovation while also promoting public donations of cord blood via the biobank, ensuring high operational standards are maintained.

For the first time in the UAE, this partnership will pave the way for the establishment of local manufacturing and clinical routes for Umbilical Cord Mesenchymal Stem Cell (UC-MSC) therapies. This approach enables the complete trajectory of treatment development within the country, from biological sample collection to therapeutic application.

Globally recognized for their potential benefits—including reducing inflammation, facilitating tissue repair, and safeguarding nerve cells—umbilical cord-derived therapies are proving promising in treating diabetes, musculoskeletal conditions, and age-related health issues, diverging from conventional symptom management.

Dr. Asma AlMannaei from the Department of Health remarked that this partnership signifies a major transition from basic cord blood donation to advanced regenerative medicine, enhancing preventive healthcare and overall quality of life.

Paul Downey, General Manager of Abu Dhabi Biobank, expressed that the collaboration effectively aligns high-quality biological data with the practical development of treatments, aiming to translate scientific research into viable medical solutions.

Masamitsu Harata, CEO of Human Life CORD, highlighted the transformative potential of stem cell therapies for chronic conditions, emphasizing that this collaborative effort brings them closer to patients by leveraging regional health data and local production.

Human Life CORD is already recognized as a leader in the field, with several of its stem cell therapies undergoing advanced clinical trials in Japan.

This partnership reflects Abu Dhabi's broader strategy to enhance medical research and innovation, while simultaneously fostering scientific collaboration between the UAE and Japan.

#Global News #UAE News #Abu Dhabi News #Abu Dhabi